| Work Detail |
Laurus Labs is enhancing its Research & Development (R&D) capabilities, focusing on a robust pipeline of new products. Satyanarayana Chava, Founder and Chief Executive Officer of Laurus Labs, announced that the company is pursuing a product-specific strategy that emphasizes complexity and economies of scale. "We have a total of 62 products in the R&D pipeline, either under review or in development, with a significant addressable market size," he stated.
In October, Laurus inaugurated its new small molecule R&D center at ICICI Knowledge Park in Hyderabad, designed to offer comprehensive development and manufacturing services. This facility aims to help innovators accelerate their clinical and commercial projects using state-of-the-art technology. "The new center has garnered strong interest from several existing biopharma clients for early-stage process development work, and we believe it will be crucial for our future growth," Chava added.
The new facility will utilize advanced techniques such as flow chemistry, biocatalysis, and high-potent chemistry, allowing Laurus to secure early-stage projects and expand its project pipeline to meet growing global partner demands. The company has also enhanced its fermentation site with a new pilot plant, which will enable it to optimize production capacity further. "Our plan to build larger fermentation capacity is on track to capitalize on GMP manufacturing opportunities," Chava noted.
In the first half of the current fiscal year, Laurus successfully underwent nearly 76 quality audits from various regulatory agencies and customers, passing all inspections without any critical findings. Chava emphasized Lauruss commitment to evolving into a respected and diversified Contract Development & Manufacturing Organization (CDMO) that meets the complex needs of its clients. "We are reinforcing this by executing our long-term investment strategy to advance our development expertise and build integrated large-scale manufacturing capabilities," he concluded. |
